Pilot Trial of Homebound Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02671448|
Recruitment Status : Active, not recruiting
First Posted : February 2, 2016
Last Update Posted : March 3, 2020
|Condition or disease||Intervention/treatment|
|Plasma Cell Dyscrasia||Behavioral: Home monitoring teleconsult visits Behavioral: Patient Reported Outcomes (PRO) Behavioral: Caregiver Reported Outcomes instruments|
|Study Type :||Observational|
|Actual Enrollment :||31 participants|
|Official Title:||Pilot Trial of Homebound Stem Cell Transplantation|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||January 2021|
|Estimated Study Completion Date :||January 2021|
Homebound After Stem Cell Transplantation
The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care.
Behavioral: Home monitoring teleconsult visits
A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
Behavioral: Patient Reported Outcomes (PRO)
Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
Behavioral: Caregiver Reported Outcomes instruments
Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
- readmission rate by 21 days post HSCT [ Time Frame: 21 days post HSCT ]the homebound procedure will be considered promising if no more than 10 patients are readmitted to the hospital within 21 days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02671448
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Heather Landau, MD||Memorial Sloan Kettering Cancer Center|